Sinovac Biotech Ltd. Files for Approval of EV71 Vaccine

by Richard Daverman, PhD

May 30, 2013 -- Sinovac Biotech reported the Beijing Drug Administration has accepted the company's filing of a New Drug Application for its novel enterovirus 71 vaccine. The vaccine, which completed its Phase III trial in March, achieved a 95% efficacy against Hand, Foot and Mouth Disease. Yesterday, Beijing Vigoo Biological, a China National Biotec unit, published data in The Lancet, revealing its EV71 vaccine had a near-identical 90% efficacy. More details....

Stock Symbol: (NSDQ: SVA)

MORE ON THIS TOPIC